Abstract
BACKGROUND: Treatment with anti-B cell antibody rituximab may ameliorate the disease course in a subgroup of patients with polyneuropathy associated with IgM monoclonal gammopathy. Polymorphisms of leukocyte IgG receptors (FcγR) that influence efficiency of antibody-dependent cell-mediated cytotoxicity determine rituximab efficacy in patients with lymphoma and autoimmune disease.
OBJECTIVE: To investigate the association of FcγRIIA and FcγRIIIA polymorphisms with the response to rituximab treatment in a cohort of patients with polyneuropathy associated with IgM monoclonal gammopathy (PNP-IgM) with and without antimyelin-associated glycoprotein antibodies.
METHODS: We determined FcγRIIA-R/H131 and FcγRIIIA-V/F158 genotypes in 27 patients with PNP-IgM using allele-specific PCR and Sanger sequencing.
RESULTS: The FcγRIIIA-V/V158 genotype was associated with functional improvement (p=0.02) after 1 year.
CONCLUSIONS: FcγRIIIA polymorphisms are potential biomarkers for response to rituximab treatment in polyneuropathy associated with IgM monoclonal gammopathy.
| Original language | English |
|---|---|
| Pages (from-to) | 918-920 |
| Number of pages | 3 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 85 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2014 |
Keywords
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived
- Cohort Studies
- Demyelinating Diseases
- Female
- Glycoproteins
- Humans
- Male
- Middle Aged
- Myelin Sheath
- Netherlands
- Neural Conduction
- Paraproteinemias
- Polymorphism, Genetic
- Polyneuropathies
- Prospective Studies
- Receptors, IgG
- Rituximab
- Treatment Outcome
- Journal Article
- Research Support, Non-U.S. Gov't
Fingerprint
Dive into the research topics of 'Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver